December 21, 2013
Telik, Inc. (Nasdaq: TELK) today reported a net loss of $4.7 million, or $0.09 per share, for the third quarter ended September 30, 2010, compared with a net loss of $6.1 million, or $0.11 per share, for the comparable period in...(read more)
Telik, Inc. (TELK), a clinical stage drug development company, focuses on discovering and developing small molecule drugs to treat cancer. Recently the company had a nice rally and jumped from...(read more)
Telik (TELK) Company Overview
There is no analysis for TELK yet. But you can go to Wikinvest to help create one!